title: Experience with daily self-administered subcutaneous erythropoietin.
authors.affiliation: Department of Nephrology, University Hospital, Nîmes, France.
authors.forename: C
authors.initials: C
authors.lastname: Granolleras
authors.forename: B
authors.initials: B
authors.lastname: Branger
authors.forename: M C
authors.initials: MC
authors.lastname: Beau
authors.forename: G
authors.initials: G
authors.lastname: Deschodt
authors.forename: B
authors.initials: B
authors.lastname: Alsabadani
authors.forename: S
authors.initials: S
authors.lastname: Shaldon
mesh_terms: D000328:Adult; D000368:Aged; D000740:Anemia / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D004921:Erythropoietin / Q000008:administration & dosage*; D005260:Female; D006400:Hematocrit; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007279:Injections, Subcutaneous; D007676:Kidney Failure, Chronic / Q000150:complications; D008297:Male; D008875:Middle Aged; D012646:Self Administration
chemical_list: D006454:Hemoglobins; D004921:Erythropoietin